0.993
price down icon1.68%   -0.017
after-market Dopo l'orario di chiusura: 1.01 0.017 +1.71%
loading
Precedente Chiudi:
$1.01
Aprire:
$0.99
Volume 24 ore:
698.39K
Relative Volume:
1.00
Capitalizzazione di mercato:
$78.11M
Reddito:
$101.21M
Utile/perdita netta:
$-569.00K
Rapporto P/E:
-1.1821
EPS:
-0.84
Flusso di cassa netto:
$-56.88M
1 W Prestazione:
-0.60%
1M Prestazione:
-13.65%
6M Prestazione:
-77.58%
1 anno Prestazione:
-21.19%
Intervallo 1D:
Value
$0.99
$1.01
Intervallo di 1 settimana:
Value
$0.9886
$1.07
Portata 52W:
Value
$0.9882
$5.85

Cytomx Therapeutics Inc Stock (CTMX) Company Profile

Name
Nome
Cytomx Therapeutics Inc
Name
Telefono
650.515.3185
Name
Indirizzo
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Name
Dipendente
122
Name
Cinguettio
@cytomxinc
Name
Prossima data di guadagno
2024-11-07
Name
Ultimi documenti SEC
Name
CTMX's Discussions on Twitter

Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-05-28 Aggiornamento Piper Sandler Neutral → Overweight
2024-05-09 Aggiornamento Wedbush Neutral → Outperform
2024-05-06 Aggiornamento Jefferies Hold → Buy
2024-04-22 Aggiornamento JP Morgan Underweight → Neutral
2022-11-14 Downgrade BMO Capital Markets Outperform → Market Perform
2022-07-07 Downgrade Jefferies Buy → Hold
2022-07-07 Downgrade Mizuho Buy → Neutral
2022-07-07 Downgrade Piper Sandler Overweight → Neutral
2022-07-07 Downgrade Wedbush Outperform → Neutral
2022-06-24 Iniziato BMO Capital Markets Outperform
2022-01-18 Aggiornamento Barclays Underweight → Overweight
2021-11-15 Iniziato BTIG Research Buy
2021-05-28 Downgrade Barclays Equal Weight → Underweight
2021-03-29 Iniziato JP Morgan Overweight
2021-03-23 Aggiornamento Jefferies Hold → Buy
2020-09-22 Downgrade Guggenheim Buy → Neutral
2020-06-01 Downgrade Jefferies Buy → Hold
2020-05-14 Reiterato H.C. Wainwright Buy
2020-03-24 Aggiornamento Wedbush Neutral → Outperform
2020-03-04 Iniziato Barclays Equal Weight
2019-11-20 Iniziato Guggenheim Buy
2019-11-11 Downgrade Wedbush Outperform → Neutral
2019-06-13 Iniziato Mizuho Buy
2019-05-14 Iniziato Cantor Fitzgerald Overweight
2019-03-11 Iniziato Barclays Overweight
2018-11-26 Iniziato Piper Jaffray Overweight
2018-10-15 Iniziato Goldman Neutral
2018-09-13 Iniziato H.C. Wainwright Buy
2018-06-01 Iniziato SunTrust Buy
2018-01-05 Iniziato Citigroup Buy
2017-09-08 Iniziato Wedbush Outperform
2017-03-27 Iniziato H.C. Wainwright Buy
2017-03-02 Iniziato Instinet Buy
2017-01-03 Downgrade Oppenheimer Outperform → Perform
2015-11-02 Iniziato Oppenheimer Outperform
Mostra tutto

Cytomx Therapeutics Inc Borsa (CTMX) Ultime notizie

pulisher
Nov 03, 2024

Analysts Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) Price Target at $5.77 - Defense World

Nov 03, 2024
pulisher
Nov 01, 2024

CytomX Therapeutics (CTMX) Set to Announce Earnings on Thursday - MarketBeat

Nov 01, 2024
pulisher
Oct 31, 2024

CytomX Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024 - The Manila Times

Oct 31, 2024
pulisher
Oct 31, 2024

Analysts Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) PT at $5.77 - MarketBeat

Oct 31, 2024
pulisher
Oct 26, 2024

Investors Aren't Buying CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues - Simply Wall St

Oct 26, 2024
pulisher
Oct 25, 2024

CytomX stock plunges to 52-week low at $1.03 amid market challenges - Investing.com India

Oct 25, 2024
pulisher
Oct 25, 2024

CytomX stock plunges to 52-week low at $1.03 amid market challenges By Investing.com - Investing.com South Africa

Oct 25, 2024
pulisher
Oct 17, 2024

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Short Interest Down 10.5% in September - MarketBeat

Oct 17, 2024
pulisher
Oct 15, 2024

CytomX Therapeutics Inc (CTMX) rating upgrades by Piper Sandler - Knox Daily

Oct 15, 2024
pulisher
Oct 15, 2024

Trading Day Triumph: CytomX Therapeutics Inc (CTMX) Ends at 1.09, a -5.22 Surge/Plunge - The Dwinnex

Oct 15, 2024
pulisher
Oct 15, 2024

CTMX Stock: A Comprehensive Analysis and Forecast - The InvestChronicle

Oct 15, 2024
pulisher
Oct 13, 2024

Squarepoint Ops LLC Has $243,000 Stock Position in CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Defense World

Oct 13, 2024
pulisher
Oct 11, 2024

Selling Buzz: CytomX Therapeutics Inc [CTMX] Chief Business Officer Landau Jeffrey B sells 4,181 shares of the company – Knox Daily - Knox Daily

Oct 11, 2024
pulisher
Oct 06, 2024

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Oct 06, 2024
pulisher
Sep 30, 2024

There is no way CytomX Therapeutics Inc (CTMX) can keep these numbers up - SETE News

Sep 30, 2024
pulisher
Sep 29, 2024

Forefront Analytics LLC Has $78,000 Stock Position in CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Defense World

Sep 29, 2024
pulisher
Sep 27, 2024

Wall Street SWOT: CytomX Therapeutics stock shows promise amid clinical trials - Investing.com

Sep 27, 2024
pulisher
Sep 27, 2024

CytomX Therapeutics Inc [NASDAQ: CTMX] Sees Increase in Stock Value - Knox Daily

Sep 27, 2024
pulisher
Sep 26, 2024

Investors in cash trouble should check out CytomX Therapeutics Inc (CTMX) - SETE News

Sep 26, 2024
pulisher
Sep 25, 2024

Is it possible to buy CytomX Therapeutics Inc(CTMX) shares at a good price now? - US Post News

Sep 25, 2024
pulisher
Sep 25, 2024

Metastatic Cancer Drugs Market Outlook, Insights, and Size: 2024-2033 - WhaTech

Sep 25, 2024
pulisher
Sep 24, 2024

CTMX stock rated an Overweight by Piper Sandler - Knox Daily

Sep 24, 2024
pulisher
Sep 24, 2024

Investor’s Toolkit: Key Ratios for Assessing CytomX Therapeutics Inc (CTMX)’s Performance - The Dwinnex

Sep 24, 2024
pulisher
Sep 24, 2024

Altamira Therapeutics Reports Narrowed Losses - TipRanks

Sep 24, 2024
pulisher
Sep 24, 2024

CytoDyn Announces Preliminary Findings in Study with SMC Laboratories - StockTitan

Sep 24, 2024
pulisher
Sep 24, 2024

Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results - StockTitan

Sep 24, 2024
pulisher
Sep 24, 2024

This trade activity should not be overlooked: Cytokinetics Inc (CYTK) - SETE News

Sep 24, 2024
pulisher
Sep 24, 2024

Cytokinetics, Incorporated (NASDAQ:CYTK) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Sep 24, 2024
pulisher
Sep 23, 2024

Immix (IMMX) CAR-T Therapy IND Cleared by FDA, Stock Down - MSN

Sep 23, 2024
pulisher
Sep 22, 2024

XTX Topco Ltd Makes New $889,000 Investment in Churchill Downs Incorporated (NASDAQ:CHDN) - MarketBeat

Sep 22, 2024
pulisher
Sep 21, 2024

Renaissance Technologies LLC Takes Position in ChampionX Co. (NASDAQ:CHX) - MarketBeat

Sep 21, 2024
pulisher
Sep 21, 2024

Tucows Inc. (NASDAQ:TCX) CEO Elliot Noss Sells 5,700 Shares of Stock - Defense World

Sep 21, 2024
pulisher
Sep 21, 2024

622,616 Shares in ChampionX Co. (NASDAQ:CHX) Bought by Renaissance Technologies LLC - Defense World

Sep 21, 2024
pulisher
Sep 20, 2024

Coherent (COHR) Soars 6.3%: Is Further Upside Left in the Stock? - Yahoo Finance

Sep 20, 2024
pulisher
Sep 20, 2024

CTMX: A Tale of Ups & Downs – -48.46% loss in 6 Months, -5.65% in 30 Days - The InvestChronicle

Sep 20, 2024
pulisher
Sep 20, 2024

Insider Selling: Landau Jeffrey B, CytomX Therapeutics Inc [CTMX] Chief Business Officer divested 4,181 shares - Knox Daily

Sep 20, 2024
pulisher
Sep 20, 2024

Choreo LLC Purchases Shares of 23,033 Coty Inc. (NYSE:COTY) - Defense World

Sep 20, 2024
pulisher
Sep 19, 2024

Top 2% Biotech Hits Slam Dunk On Bid To Edge Out Bristol, Cytokinetics - Investor's Business Daily

Sep 19, 2024
pulisher
Sep 19, 2024

Coherent Corp (COHR)’s Market Momentum: Closing Strong at 80.98, Up 3.93 - The Dwinnex

Sep 19, 2024
pulisher
Sep 19, 2024

Autolus Therapeutics (AUTL) Appoints Matthias Will as Chief Development Officer - StreetInsider.com

Sep 19, 2024
pulisher
Sep 18, 2024

Analyzing CTMX’s price-to-book ratio for the last quarter - US Post News

Sep 18, 2024
pulisher
Sep 17, 2024

Altamira Therapeutics prices up to $12M public offering - MSN

Sep 17, 2024
pulisher
Sep 16, 2024

Keeping an Eye on CytomX Therapeutics Inc (CTMX) After Insider Trading Activity - Knox Daily

Sep 16, 2024
pulisher
Sep 16, 2024

Check Out CytomX Therapeutics Inc (CTMX)’s Trade Data Rather Than the Analysts’ Views - SETE News

Sep 16, 2024
pulisher
Sep 16, 2024

Gaining Ground: CytomX Therapeutics Inc (CTMX) Closes Lower at 1.23, Down -1.60 - The Dwinnex

Sep 16, 2024
pulisher
Sep 16, 2024

HC Wainwright Reaffirms Neutral Rating for CytomX Therapeutics (NASDAQ:CTMX) - Defense World

Sep 16, 2024
pulisher
Sep 13, 2024

CytomX Therapeutics (NASDAQ:CTMX) Earns Neutral Rating from HC Wainwright - MarketBeat

Sep 13, 2024
pulisher
Sep 13, 2024

Acadian Asset Management LLC Acquires 37,739 Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Defense World

Sep 13, 2024
pulisher
Sep 12, 2024

Candriam S.C.A. Invests $256,000 in CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Defense World

Sep 12, 2024
pulisher
Sep 11, 2024

Market Watch Highlights: CytomX Therapeutics Inc (CTMX) Ends on an Upturn Note at 1.31 - The Dwinnex

Sep 11, 2024
pulisher
Sep 11, 2024

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Sep 11, 2024

Cytomx Therapeutics Inc Azioni (CTMX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Cytomx Therapeutics Inc Azioni (CTMX) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Landau Jeffrey B
Chief Business Officer
Aug 20 '24
Sale
1.23
4,181
5,139
119,056
BELVIN MARCIA
SVP, Chief Scientific Officer
Aug 20 '24
Option Exercise
0.00
11,250
0
179,829
BELVIN MARCIA
SVP, Chief Scientific Officer
Aug 20 '24
Sale
1.23
4,181
5,139
175,648
ROWLAND LLOYD A
General Counsel
Aug 20 '24
Option Exercise
0.00
11,250
0
134,978
ROWLAND LLOYD A
General Counsel
Aug 20 '24
Sale
1.23
4,181
5,139
130,797
Ogden Christopher
Chief Financial Officer
Aug 20 '24
Option Exercise
0.00
6,875
0
110,061
Ogden Christopher
Chief Financial Officer
Aug 20 '24
Sale
1.23
1,984
2,439
108,077
McCarthy Sean A.
CEO
Aug 20 '24
Option Exercise
0.00
37,500
0
671,749
McCarthy Sean A.
CEO
Aug 20 '24
Sale
1.23
13,898
17,082
657,851
McCarthy Sean A.
CEO
Mar 26 '24
Option Exercise
1.57
109,768
172,874
634,249
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Capitalizzazione:     |  Volume (24 ore):